These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37174740)

  • 1. T Regulatory Cell-Associated Tolerance Induction by High-Dose Immunoglobulins in an HLA-Transgenic Mouse Model of Pemphigus.
    Hudemann C; Hoffmann J; Schmidt E; Hertl M; Eming R
    Cells; 2023 May; 12(9):. PubMed ID: 37174740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
    Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
    Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
    Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
    J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Ig Regulates Anti-Desmoglein 3 IgG Production in B220
    Kase Y; Takahashi H; Ito H; Kamata A; Amagai M; Yamagami J
    J Invest Dermatol; 2022 Jul; 142(7):1786-1792.e3. PubMed ID: 34848195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.
    Mimouni D; Blank M; Payne AS; Anhalt GJ; Avivi C; Barshack I; David M; Shoenfeld Y
    Clin Exp Immunol; 2010 Dec; 162(3):543-9. PubMed ID: 20964642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
    Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
    Front Immunol; 2018; 9():1935. PubMed ID: 30233569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Desmocollin 3‒Specific IgG Antibodies Are Pathogenic in a Humanized HLA Class II Transgenic Mouse Model of Pemphigus.
    Hudemann C; Maglie R; Llamazares-Prada M; Beckert B; Didona D; Tikkanen R; Schmitt T; Hashimoto T; Waschke J; Hertl M; Eming R
    J Invest Dermatol; 2022 Mar; 142(3 Pt B):915-923.e3. PubMed ID: 34265330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
    Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M
    J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice.
    Takahashi H; Kouno M; Nagao K; Wada N; Hata T; Nishimoto S; Iwakura Y; Yoshimura A; Yamada T; Kuwana M; Fujii H; Koyasu S; Amagai M
    J Clin Invest; 2011 Sep; 121(9):3677-88. PubMed ID: 21821914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inducible costimulator expressed on CXCR5
    Kim AR; Han D; Choi JY; Seok J; Kim SE; Seo SH; Takahashi H; Amagai M; Park SH; Kim SC; Shin EC; Kim JH
    J Allergy Clin Immunol; 2020 Nov; 146(5):1070-1079.e8. PubMed ID: 32311391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational epitope mapping of antibodies against desmoglein 3 in experimental murine pemphigus vulgaris.
    Anzai H; Fujii Y; Nishifuji K; Aoki-Ota M; Ota T; Amagai M; Nishikawa T
    J Dermatol Sci; 2004 Aug; 35(2):133-42. PubMed ID: 15265525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
    Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M
    J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.
    Mimouni D; Blank M; Ashkenazi L; Milner Y; Frusic-Zlotkin M; Anhalt GJ; David M; Shoenfeld Y
    Clin Exp Immunol; 2005 Dec; 142(3):426-32. PubMed ID: 16297153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice.
    Aoki-Ota M; Tsunoda K; Ota T; Iwasaki T; Koyasu S; Amagai M; Nishikawa T
    Br J Dermatol; 2004 Aug; 151(2):346-54. PubMed ID: 15327541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single helper T cell clone is sufficient to commit polyclonal naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris.
    Takahashi H; Kuwana M; Amagai M
    J Immunol; 2009 Feb; 182(3):1740-5. PubMed ID: 19155523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.
    Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z
    J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model.
    Aoki-Ota M; Kinoshita M; Ota T; Tsunoda K; Iwasaki T; Tanaka S; Koyasu S; Nishikawa T; Amagai M
    J Invest Dermatol; 2006 Jan; 126(1):105-13. PubMed ID: 16417225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
    Hertl M; Riechers R
    J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
    Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
    J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
    Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
    J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.